8-K
filed June 12, 2026, 4:01 PM ET
ticker CRVS
CIK 0001626971
other material
confidence high
sentiment neutral
materiality 0.15
Corvus stockholders re-elect Miller, Grais; ratify PwC as FY 2026 auditor
Corvus Pharmaceuticals, Inc.
- Richard A. Miller and Linda S. Grais elected as Class I directors with 58.3M and 53.2M votes for, respectively; 12.0M broker non-votes.
- Ratification of PricewaterhouseCoopers as independent auditor: 72.9M for, 105.7k against, 51.8k abstain.
- Non-binding advisory approval of NEO compensation: 58.9M for, 1.97M against, 64.3k abstain; 12.0M broker non-votes.
- 73.0M shares voted out of 84.1M shares outstanding as of record date April 16, 2026.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Corvus Pharmaceuticals, Inc. shareholders approved Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2026-06-11 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal No. 3 —Non-Binding Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers On a non-binding advisory basis, the Company’s stockholders approved the compensation of the Company’s named executive officers. Votes For Votes Against Abstain Broker Non-Votes 58,936,532 1,971,370 64,329 12,049,623
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Corvus Pharmaceuticals, Inc. shareholders approved Election of Class I Directors at the 2026-06-11 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal No. 1 — Election of Directors The Company’s stockholders elected the Class I director nominees below to the Company’s Board of Directors to hold office until the 2029 Annual Meeting of Stockholders or until his or her respective successor is elected and qualified or appointed, or the earlier of his or her death, resignation or removal. Class III Director Nominees Votes For Votes Withheld Broker Non - Votes Richard A. Miller, M.D. 58,275,179 2,697,052 12,049,623 Linda S. Grais, M.D., J.D. 53,185,380 7,786,851 12,049,623
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Corvus Pharmaceuticals, Inc. shareholders approved Ratification of Selection of Independent Registered Accounting Firm at the 2026-06-11 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-06-11
Exact text from the filing
Proposal No. 2 — Ratification of Selection of Independent Registered Accounting Firm The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. Votes For Votes Against Abstain 72,864,335 105,674 51,845
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.